Tarsus Pharmaceuticals, Inc.
TARS
Peringkat dalam Saham
#4544
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Harga Saham
$70.30
Kapitalisasi Pasar
$3.29B
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
2.32%
Negara
US
Perdagangan Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Riwayat harga saham Tarsus Pharmaceuticals, Inc. (TARS)
Harga penutupan tertinggi: $72.12 pada 2026-10-01
Harga penutupan terendah: $21.51 pada 2020-10-01
Harga penutupan terendah: $21.51 pada 2020-10-01
Riwayat harga saham Tarsus Pharmaceuticals, Inc. dari 2020 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $530.66 | 24.44% |
US
|
|
| $230.18 | 757.28% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.66 | 9.40% |
NL
|
|
| $290.41 | 2.03% |
BE
|
